Centessa Pharmaceuticals

Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonist Therapies

By BiotechReality Business Intelligence Desk
24 June 2026

Eli Lilly and Company has announced the successful completion of its acquisition of Centessa Pharmaceuticals plc, integrating a clinical-stage portfolio of orexin receptor 2 agonists to address severe sleep-wake disorders.

Business Healthcare & Pharmaceuticals News

Lilly Acquires Centessa Pharmaceuticals to Transform Sleep-Wake Disorder Treatments

By BiotechReality Business Intelligence Desk
31 March 2026

Eli Lilly and Company has announced a definitive agreement to acquire Centessa Pharmaceuticals for up to $7.8 billion, signaling a major expansion into the sleep medicine market through innovative orexin receptor agonists.

Tag: Centessa Pharmaceuticals

Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonist Therapies

Lilly Acquires Centessa Pharmaceuticals to Transform Sleep-Wake Disorder Treatments

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement